Clinical Commander

Back to dossier
cardio.atrial_flutter.with-cardiogenic-shock.v1PRODUCTION
cardio.atrial_flutter.with-cardiogenic-shock.v1

Atrial flutter precipitating cardiogenic shock (AFL with RVR + low-output state)

cardiologyacuteadult
Hard-required inputs
0 / 14
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Atrial flutter precipitating cardiogenic shock — AFL RVR + loss of atrial kick + tachycardia-mediated cardiomyopathy → SCAI B-C low-output state, especially in HFrEF / severe valvular / elderly. Two parallel decisions: (1) restore atrial mechanical contribution via emergent DCCV (Class I per ACC/AHA 2024 PMID 38753446); (2) inotropic + vasopressor support for shock (NE for MAP, dobutamine for CI) per SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)

Inputs
2
Actions
0
Advance rule
Set
Advance when

AFL + shock confirmed; substrate identified

Patient inputs (15)

Elderly / frail patients have limited inotropic reserve; CHA2DS2-VASc; informs MCS candidacy + cardiothoracic surgery decision

AFL RVR HR 130–180+ with conduction ratio 2:1 most common; HR target post-CV restoration sinus rhythm

HFrEF / severe MS / severe AS / HCM substrate predicts shock vulnerability; gates anticipatory ICU admission + early MCS evaluation

Elevated BNP / NT-proBNP confirms acute heart failure component; trend post-CV reflects atrial-kick restoration benefit

Troponin elevation indicates demand ischemia from RVR or concomitant ACS; gates acs_pathway routing if persistent rise

AKI common in shock (cardiorenal); eGFR for DOAC dose; trend monitors end-organ response

K+ ≥4 and Mg ≥2 mandatory before DCCV (reduces post-CV arrhythmia risk); replete urgently

Confirm AFL morphology + conduction ratio; rule out STEMI mimic; baseline QTc before any AAD

Bedside echo: LVEF, valvular function (severe MS/AS where atrial kick is critical), pericardial effusion, RV function, LA size, thrombus screen — drives MCS decision and post-CV surveillance

SBP <90 with AFL = SCAI B-C shock; gates emergent synchronized DCCV (ACC/AHA 2024 Class I); MAP <65 triggers norepinephrine; serial trend after CV/inotrope

Hypoxemia from acute pulmonary edema; gates BiPAP / HFNC / intubation; pre-oxygenation critical given hemodynamic fragility for DCCV procedural sedation

Lactate ≥2 mmol/L confirms tissue hypoperfusion → SCAI B-C; serial q1–2h tracks response to CV + inotrope; lactate clearance predicts survival

CHA2DS2-VASc for AFL stroke risk; in shock context lifelong AC indicated regardless of score given cardiomyopathy substrate

HAS-BLED for AC bleed risk; informs heparin bridge + DOAC selection

TEE if cardioversion delayed beyond 48 h without therapeutic AC OR if AFL duration uncertain — excludes LAA thrombus before CV; if hemodynamically unstable, do not delay CV for TEE — proceed with heparin bolus then CV (ACC/AHA 2024)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningfailed_DCCV_at_maximum_energy
    Failed synchronized DCCV at maximum biphasic energy (200 J × 2 attempts) in unstable AFL — escalate to chemical CV with ibutilide if QTc safe + electrolytes repleted, else amiodarone load + reassess
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningelectrical_storm_with_aflutter_and_shock
    Recurrent AFL with hemodynamic instability requiring ≥3 cardioversions in 24 h despite AAD — electrical storm pattern in arrhythmic shock
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrefractory_shock_needing_MCS
    SCAI C+ shock refractory to NE + dobutamine + CV — MCS escalation indicated (Impella CP per DanGer Shock; IABP; VA-ECMO)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningembolic_stroke_during_cardioversion
    Acute focal neuro deficit during or within 24 h of CV in patient without prior therapeutic AC — embolic stroke from LAA thrombus
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmajor_bleed_in_AFL_with_CS_dual_indication
    Major bleeding (intracranial, GI requiring transfusion, retroperitoneal, hemodynamic compromise) on AC + invasive lines + MCS in AFL+CS context
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

AFL precipitating cardiogenic shock — emergent synchronized DCCV + inotrope/pressor support + cautious pharmacologic rate control + AC bridge to DOAC + long-term CTI ablation pathway — ACC/AHA 2024 (PMID 38753446) + SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)
axis: aflutter_with_cardiogenic_shock_emergent_pathway
Selected axis "AFL precipitating cardiogenic shock — emergent synchronized DCCV + inotrope/pressor support + cautious pharmacologic rate control + AC bridge to DOAC + long-term CTI ablation pathway — ACC/AHA 2024 (PMID 38753446) + SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)" by default fallback (first axis)
  • synchronized_DCCV_100J_biphasic
    first line
    electrical_cardioversion
    100 J synchronized biphasic; escalate to 200 J if unsuccessful; pre-treat with K ≥4 + Mg ≥2 • electrical • single shock; may repeat at higher energy
    triggers: aflutter_with_sbp_below_90, aflutter_with_acute_pulmonary_edema, hemodynamic_instability_with_aflutter_RVR
    ACC/AHA 2024 Class I (PMID 38753446) — only intervention restoring atrial kick acutely; flutter cardioverts at lower energies than AF; do not delay for TEE if unstable — give heparin bolus then proceed
  • unfractionated_heparin
    first line
    heparin
    60 U/kg IV bolus (max 5000 U) → 12 U/kg/h infusion (max 1000 U/h) titrate to PTT 1.5–2× control or anti-Xa 0.3–0.7 • IV • bolus + continuous
    triggers: pre_DCCV_AC_bridge_in_unstable_aflutter, pre_oral_DOAC_initiation_phase
    Bridge AC for emergent CV when prior AC absent — ACC/AHA 2024 (PMID 38753446); reversible; preferred over LMWH given titratability + reversal options in shock context
    rxcui 5224
  • norepinephrine
    first line
    vasopressor
    0.05–0.5 mcg/kg/min IV titrate to MAP ≥65 • IV • continuous
    triggers: SBP_below_90_or_MAP_below_65_after_initial_resuscitation, SCAI_B_or_C_shock_with_aflutter
    First-line vasopressor in cardiogenic shock per SCAI 2022 (PMID 35718438); preserves coronary perfusion + improves MAP without excessive tachycardia worsening RVR
    rxcui 7512
  • dobutamine
    first line
    inotrope_beta1_agonist
    2.5–10 mcg/kg/min IV titrate to CI ≥2.2 L/min/m^2 • IV • continuous
    triggers: low_cardiac_index_with_adequate_MAP_post_NE, HFrEF_substrate_with_aflutter_decompensation
    β1-inotropic support for low CI; cautious in active arrhythmia substrate (may worsen tachycardia) — titrate to lowest effective dose; SCAI 2022 (PMID 35718438)
    rxcui 3616
  • esmolol
    second line
    short_acting_beta_blocker
    500 mcg/kg IV bolus → 25–100 mcg/kg/min infusion (start LOW given hypoperfusion); avoid if SBP <100 or worsening shock • IV • bolus + continuous
    triggers: rate_control_attempt_after_failed_DCCV_with_BP_recovered, CV_temporarily_declined_or_delayed_with_HR_above_140
    Ultra-short half-life (~9 min) allows rapid titration / discontinuation if hypotension worsens — preferred over metoprolol in shock context — ACC/AHA 2024
    rxcui 203222
  • diltiazem
    comorbidity specific
    non_DHP_CCB
    REDUCED DOSE: 0.15 mg/kg IV (NOT full 0.25 mg/kg); avoid if EF <40 or SBP <100 — relatively contraindicated in HFrEF substrate • IV • cautious bolus only
    triggers: rate_control_with_preserved_EF_and_BB_intolerance, no_HFrEF_substrate
    AVOID in HFrEF (negative inotropy worsens shock); reduced dose only if EF preserved + BP recovered — ACC/AHA 2024 (PMID 38753446)
    rxcui 3443
  • amiodarone
    second line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h • IV • load + infusion
    triggers: failed_DCCV_at_max_energy, rate_control_in_HFrEF_where_BB_CCB_unsuitable, rhythm_maintenance_post_CV_with_structural_heart_disease
    Acceptable in HFrEF + structural heart disease; minimal negative inotropy vs other AADs; pulm/thyroid/hepatic toxicity with chronic use — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • ibutilide
    second line
    class_III_AAD
    1 mg IV over 10 min (0.01 mg/kg if <60 kg); may repeat × 1; baseline QTc <440 + K ≥4 + Mg ≥2 mandatory • IV • single dose, may repeat once with QT monitoring
    triggers: failed_DCCV_with_stable_BP, chemical_CV_alternative_when_DCCV_contraindicated
    Highly effective for flutter (~60% conversion); ~3% torsades risk requires K + Mg repletion + 4 h QT monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 41289
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: post_CV_AC_initiation_within_24h, CHA2DS2_VASc_>=2_in_long_term
    Mandatory ≥4 weeks post-CV regardless of CHA2DS2-VASc; lifelong if AFL persistent or cardiomyopathy substrate; ARISTOTLE (PMID 21870978); ACC/AHA 2024 Class I (PMID 38753446)
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) • PO • once daily
    triggers: apixaban_unavailable, once_daily_compliance_preference
    ROCKET-AF (PMID 21830957); X-VeRT data extends to flutter; ACC/AHA 2024
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3; bridge with UFH until therapeutic ×24h • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis_substrate, antiphospholipid_syndrome_triple_positive, DOAC_contraindicated
    Mechanical valve / severe MS / triple-positive APS only — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289

outpatient playbook — drug actions (3)

  1. 1. continue DOAC lifelong
    rxcui 1364430
    apixaban 5 mg BID per dose-reduction criteria • PO • BID
    trigger: Lifelong stroke + cardiomyopathy substrate
    ACC/AHA 2024
  2. 2. continue GDMT
    rxcui 1656328
    sacubitril-valsartan + carvedilol + spironolactone + empagliflozin at max tolerated • PO • as scheduled
    trigger: Persistent HFrEF
    2022 ACC/AHA HF Class I
  3. 3. wean amiodarone if successful ablation
    rxcui 703
    taper amiodarone over 4–8 weeks if no recurrence at 3 mo • PO • taper
    trigger: Successful ablation + 3-mo recurrence-free
    ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Atrial flutter on monitor + SBP <90 mmHg + signs of hypoperfusion (cool extremities, lactate ≥2, oliguria, AMS) → SCAI B-C cardiogenic shock screen with emergent DCCV indication (ACC/AHA 2024 Class I PMID 38753446); New-onset AFL with RVR + acute pulmonary edema in patient with pre-existing HFrEF or critical valvular disease — composite emergency requiring emergent DCCV before pharmacologic rate control; Known severe aortic stenosis or severe mitral stenosis with new AFL + acute decompensation (atrial kick essential to maintain stroke volume across stenotic valve).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter precipitating cardiogenic shock (AFL with RVR + low-output state)** (cardio.atrial_flutter.with-cardiogenic-shock.v1).
Phenotype framing: AFL precipitating shock vs AFL incidental in pre-existing decompensated HF vs ACS with new AFL secondary to ischemia vs PE causing AFL + RV failure (route to cardio.atrial_flutter.with-pe.v1) vs septic shock with concomitant AFL
Scope: Atrial flutter precipitating cardiogenic shock — AFL RVR + loss of atrial kick + tachycardia-mediated cardiomyopathy → SCAI B-C low-output state, especially in HFrEF / severe valvular / elderly. Two parallel decisions: (1) restore atrial mechanical contribution via emergent DCCV (Class I per ACC/AHA 2024 PMID 38753446); (2) inotropic + vasopressor support for shock (NE for MAP, dobutamine for CI) per SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)

No severity triggers fired against current inputs.

Plan

Regimen axis: **AFL precipitating cardiogenic shock — emergent synchronized DCCV + inotrope/pressor support + cautious pharmacologic rate control + AC bridge to DOAC + long-term CTI ablation pathway — ACC/AHA 2024 (PMID 38753446) + SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)**.
1. synchronized_DCCV_100J_biphasic 100 J synchronized biphasic; escalate to 200 J if unsuccessful; pre-treat with K ≥4 + Mg ≥2 electrical single shock; may repeat at higher energy (electrical_cardioversion, first line) — ACC/AHA 2024 Class I (PMID 38753446) — only intervention restoring atrial kick acutely; flutter cardioverts at lower energies than AF; do not delay for TEE if unstable — give heparin bolus then proceed
2. unfractionated_heparin 60 U/kg IV bolus (max 5000 U) → 12 U/kg/h infusion (max 1000 U/h) titrate to PTT 1.5–2× control or anti-Xa 0.3–0.7 IV bolus + continuous (heparin, first line) — Bridge AC for emergent CV when prior AC absent — ACC/AHA 2024 (PMID 38753446); reversible; preferred over LMWH given titratability + reversal options in shock context
3. norepinephrine 0.05–0.5 mcg/kg/min IV titrate to MAP ≥65 IV continuous (vasopressor, first line) — First-line vasopressor in cardiogenic shock per SCAI 2022 (PMID 35718438); preserves coronary perfusion + improves MAP without excessive tachycardia worsening RVR
4. dobutamine 2.5–10 mcg/kg/min IV titrate to CI ≥2.2 L/min/m^2 IV continuous (inotrope_beta1_agonist, first line) — β1-inotropic support for low CI; cautious in active arrhythmia substrate (may worsen tachycardia) — titrate to lowest effective dose; SCAI 2022 (PMID 35718438)
5. esmolol 500 mcg/kg IV bolus → 25–100 mcg/kg/min infusion (start LOW given hypoperfusion); avoid if SBP <100 or worsening shock IV bolus + continuous (short_acting_beta_blocker, second line) — Ultra-short half-life (~9 min) allows rapid titration / discontinuation if hypotension worsens — preferred over metoprolol in shock context — ACC/AHA 2024
6. diltiazem REDUCED DOSE: 0.15 mg/kg IV (NOT full 0.25 mg/kg); avoid if EF <40 or SBP <100 — relatively contraindicated in HFrEF substrate IV cautious bolus only (non_DHP_CCB, comorbidity specific) — AVOID in HFrEF (negative inotropy worsens shock); reduced dose only if EF preserved + BP recovered — ACC/AHA 2024 (PMID 38753446)
7. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h IV load + infusion (class_III_AAD, second line) — Acceptable in HFrEF + structural heart disease; minimal negative inotropy vs other AADs; pulm/thyroid/hepatic toxicity with chronic use — ACC/AHA 2024 (PMID 38753446)
8. ibutilide 1 mg IV over 10 min (0.01 mg/kg if <60 kg); may repeat × 1; baseline QTc <440 + K ≥4 + Mg ≥2 mandatory IV single dose, may repeat once with QT monitoring (class_III_AAD, second line) — Highly effective for flutter (~60% conversion); ~3% torsades risk requires K + Mg repletion + 4 h QT monitoring — ACC/AHA 2024 (PMID 38753446)
9. apixaban 5 mg BID (2.5 mg if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — Mandatory ≥4 weeks post-CV regardless of CHA2DS2-VASc; lifelong if AFL persistent or cardiomyopathy substrate; ARISTOTLE (PMID 21870978); ACC/AHA 2024 Class I (PMID 38753446)
10. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) PO once daily (DOAC_factor_Xa, first line) — ROCKET-AF (PMID 21830957); X-VeRT data extends to flutter; ACC/AHA 2024
11. warfarin 5 mg daily; INR target 2–3; bridge with UFH until therapeutic ×24h PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS / triple-positive APS only — ACC/AHA 2024 (PMID 38753446)

Setting playbook (outpatient) — Long-term AFL + cardiomyopathy management: lifelong DOAC, post-ablation surveillance, GDMT maintenance, CTEPH/valve disease monitoring, primary prevention of recurrence — ACC/AHA 2024 + 2022 ACC/AHA HF
12. continue DOAC lifelong apixaban 5 mg BID per dose-reduction criteria PO BID — Lifelong stroke + cardiomyopathy substrate (ACC/AHA 2024)
13. continue GDMT sacubitril-valsartan + carvedilol + spironolactone + empagliflozin at max tolerated PO as scheduled — Persistent HFrEF (2022 ACC/AHA HF Class I)
14. wean amiodarone if successful ablation taper amiodarone over 4–8 weeks if no recurrence at 3 mo PO taper — Successful ablation + 3-mo recurrence-free (ACC/AHA 2024)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase
- LAA occlusion (Watchman) consideration if AC contraindicated long-term — ACC/AHA 2024
- Repeat ablation if recurrence post-CTI
- Valve replacement post-op surveillance if applicable
- Lifestyle: BP, weight, alcohol, OSA, exercise

AVOID / contraindication checks:
- Full_dose_BB_or_non_DHP_CCB_AVOID_with_HFrEF_or_SBP_below_100 (ACC/AHA 2024 PMID 38753446)
- Diltiazem_verapamil_AVOID_if_EF_below_40 (ACC/AHA 2024)
- Dobutamine_caution_in_active_arrhythmia_may_worsen_tachycardia (SCAI 2022 PMID 35718438)
- Do_not_delay_DCCV_for_TEE_if_hemodynamically_unstable (ACC/AHA 2024 Class I — heparin bolus then CV)
- K_must_be_>=4_and_Mg_must_be_>=2_pre_DCCV_and_pre_AAD (ACC/AHA 2024)
- Ibutilide_baseline_QTc_<440_and_4h_post_dose_QT_monitoring (ACC/AHA 2024)
- Warfarin_only_for_mechanical_valve_severe_MS_triple_positive_APS (ACC/AHA 2024)
- Amiodarone_pulm_thyroid_hepatic_toxicity_monitor_q6m_chronic_use (ACC/AHA 2024)

Monitoring

Regimen monitoring:
- BP q5min during CV then q15min x 2h then q1h — ACC/AHA 2024
- continuous telemetry for AFL recurrence and post CV arrhythmia — ACC/AHA 2024
- lactate q1h until normalized — SCAI 2022 (PMID 35718438)
- serial echo q24h x 48h for LV recovery and atrial function — ACC/AHA 2024
- PTT q6h on UFH or anti-Xa q12h — standard
- daily K Mg BMP — ACC/AHA 2024
- daily QTc on AAD — ACC/AHA 2024
- 4-week post CV AC continuation regardless of CHA2DS2 VASc — ACC/AHA 2024 Class I (PMID 38753446)
- lifelong AC if AFL persistent or cardiomyopathy substrate — ACC/AHA 2024

Setting (outpatient) monitoring:
- Quarterly clinic + annual echo
- CBC + eGFR q6m on DOAC
- Holter at 6 + 12 mo post-ablation

Follow-up plan: Cardiology + EP follow-up at week 1 + month 1; advanced HF follow-up if HFrEF; CTI ablation booked at 4–8 weeks if typical AFL + recurrent decompensation (Calkins 2007 PMID 17572388); valve replacement / repair if MS/AS substrate driving recurrence; cardiac rehab; lifelong AC per CHA2DS2-VASc + cardiomyopathy substrate
- Close-out criterion: follow-up booked + ablation/valve pathway documented

Monitoring phase: Continuous telemetry; A-line + central line for tight hemodynamic management; serial lactate q1–2h until normalized; serial echo q24h to track LV recovery + atrial mechanical function; PTT q6h on heparin; daily K/Mg/BMP; daily ECG for AFL recurrence; QTc daily on AAD

Disposition

Current setting: outpatient — Long-term AFL + cardiomyopathy management: lifelong DOAC, post-ablation surveillance, GDMT maintenance, CTEPH/valve disease monitoring, primary prevention of recurrence — ACC/AHA 2024 + 2022 ACC/AHA HF

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 or cardio.hf.core.v1 as substrate dictates

Escalation triggers (move to higher acuity):
- Recurrent AFL with shock substrate → return to ED + ICU + repeat ablation
- Worsening HF → advanced HF / transplant evaluation
- Major bleed → reverse + LAA occlusion candidacy

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Failed synchronized DCCV at maximum biphasic energy (200 J × 2 attempts) in unstable AFL — escalate to chemical CV with ibutilide if QTc safe + electrolytes repleted, else amiodarone load + reassess
- [LIFE_THREATENING] Recurrent AFL with hemodynamic instability requiring ≥3 cardioversions in 24 h despite AAD — electrical storm pattern in arrhythmic shock
- [LIFE_THREATENING] SCAI C+ shock refractory to NE + dobutamine + CV — MCS escalation indicated (Impella CP per DanGer Shock; IABP; VA-ECMO)

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + SCAI 2022 CS staging (Baran PMID 35718438) + DanGer Shock 2024 (Møller PMID 38587234) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 38587234) [PMID:38587234](https://pubmed.ncbi.nlm.nih.gov/38587234/)
- Cited evidence (PMID 30883054) [PMID:30883054](https://pubmed.ncbi.nlm.nih.gov/30883054/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + SCAI 2022 CS staging (Baran PMID 35718438) + DanGer Shock 2024 (Møller PMID 38587234) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 38587234) — PMID:38587234
  • Cited evidence (PMID 30883054) — PMID:30883054